Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Cash from Financing Activities (2016 - 2025)

Bio-Techne (TECH) has 17 years of Cash from Financing Activities data on record, last reported at -$49.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 41.57% year-over-year to -$49.0 million; the TTM value through Dec 2025 reached -$251.7 million, down 21.05%, while the annual FY2025 figure was -$253.9 million, 107.44% down from the prior year.
  • Cash from Financing Activities reached -$49.0 million in Q4 2025 per TECH's latest filing, down from -$44.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $150.8 million in Q1 2023 and bottomed at -$90.5 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is -$31.4 million, with a median of -$52.9 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 363.17% in 2021, then crashed 282.02% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$53.4 million in 2021, then crashed by 35.26% to -$72.2 million in 2022, then dropped by 12.75% to -$81.4 million in 2023, then dropped by 3.0% to -$83.8 million in 2024, then surged by 41.57% to -$49.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$49.0 million in Q4 2025, -$44.2 million in Q3 2025, and -$90.5 million in Q2 2025.